Monday, January 3, 1994
U.S. Bioscience Inc.
(UBS), West Conshohocken, Penn.
Alex. Brown & Sons analyst David Webber lowered his rating to "neutral" from "buy" after the FDA requested additional analyses and data from UBS's Phase III trial of its Ethyol
chemoprotectant drug in advanced ovarian